LIAN Stock Price, Chart, Stats & News
LianBio (LIAN) is a dividend-paying stock with a current dividend yield of 0.00% as of Jun 17, 2025. It pays $0 per share over the trailing twelve months and distributes annually.
Dividend safety
Dividend coverage looks healthy — LIAN pays out about 0% of earnings.
LIAN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.30% |
ROA | -34.47% |
ROE | -35.96% |
D/E | 0.02x |
Interest coverage ratio | – |
LIAN valuation
P/E | – |
P/S | – |
P/B | 0.13x |
P/CF | -0.35x |
P/FCF | -0.34x |
P/OCF | -0.35x |
PEG | -0.00x |
EV multiple | -0.88x |
About
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus.
Related lists
Similar securities
Based on sector and market capitalization
